Literature DB >> 23278488

Microalbuminuria: a neglected cardiovascular risk factor in non-diabetic individuals?

Eirini Lioudaki1, Matilda Florentin, Emmanuel S Ganotakis, Dimitri P Mikhailidis.   

Abstract

Microalbuminuria (MA), excessive albumin excretion in the urine, is defined in different ways. MA is more prevalent among patients with diabetes mellitus (DM) and/or hypertension and correlates with adverse renal and cardiovascular (CV) outcomes. Several cross-sectional and prospective studies have demonstrated a positive association between MA and CV outcomes in the general population but also specific populations such as patients with previous MI and hypertensives. The relationship between MA and hypertension is of particular importance. Increased urine albumin excretion (UAE) has been associated with left ventricular hypertrophy (LVH), subclinical markers of atherosclerosis and vascular dysfunction. Metabolic syndrome (MetS), insulin resistance (IR), inflammatory markers, lipid parameters and measures of obesity also correlate with increased UAE. Accumulating evidence suggests that a UAE value lower than the "traditionally" considered microalbuminuric threshold is associated with increased CV risk. The revision of MA definition according to the levels which confer increased CV risk in the general population should probably be considered. Further prospective studies with uniform methods of urine collection and UAE measurement as well as consistent threshold values and units may provide additional information regarding MA (or low-grade albuminuria) as a predictor of CV outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23278488     DOI: 10.2174/1381612811319270019

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  4 in total

Review 1.  Recent advances in understanding hypertension development in sub-Saharan Africa.

Authors:  A E Schutte; S Botha; C M T Fourie; L F Gafane-Matemane; R Kruger; L Lammertyn; L Malan; C M C Mels; R Schutte; W Smith; J M van Rooyen; L J Ware; H W Huisman
Journal:  J Hum Hypertens       Date:  2017-03-23       Impact factor: 3.012

Review 2.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

3.  Significance of normal range urinary albumin to creatinine ratio in Chinese subjects with metabolic syndrome.

Authors:  Jing Hong; Jin-Ping Zhang; Ling-Ting Xie; Yi-Fan He; Yan-Yu Lv; Hong Jiang; Xiao-Yan Xing
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-12-16

4.  Ghrelin Levels and Decreased Kidney Function in Patients with Early Stages of Chronic Kidney Disease Against the Background of Obesity.

Authors:  Nataliia Vasylivna Gubina; Iryna Hryhorivna Kupnovytska; Vasyl Hryhorovych Mishchuk; Halyna Dmytrivna Markiv
Journal:  J Med Life       Date:  2020 Oct-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.